Depressive symptoms are among early behavioral changes in Alzheimer’s disease (AD); however, the relationship between neurodegeneration and depressive symptoms remains inconclusive. To better understand this relationship in preclinical AD, we examined hippocampal volume and depressive symptoms in cognitively unimpaired carriers of the presenilin-1 (PSEN1) E280A mutation for autosomal dominant AD.
A total of 27 PSEN1 mutation carriers and 26 non-carrier family members were included. Linear regression was used to test the relationship between hippocampal volume and 15-item Geriatric Depression Scale.
Carriers and non-carriers did not differ in depressive symptoms or hippocampal volume. Within carriers, lower hippocampal volume was associated with greater depressive symptoms, which remained significant after adjusting for age and cognition. This relationship was not significant in non-carriers.
Hippocampal neurodegeneration may underlie depressive symptoms in preclinical autosomal dominant AD. These findings provide support for the utility of targeting depressive symptoms in AD prevention.
We compared unimpaired autosomal dominant Alzheimer’s disease (AD) mutation carriers and non-carriers.
Carriers and non-carriers did not differ in severity of depressive symptoms.
In carriers, hippocampal volume was inversely associated with depressive symptoms.
Depressive symptoms may be a useful target in AD prevention.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Stephanie Langella,
Joshua T. Fox‐Fuller,
Jairo E. Martinez,
Bernard J. Hanseeuw,
Gad A. Marshall,
Yakeel T. Quiroz,
Jennifer R. Gatchel | October 14, 2023